Drug Type Universal CAR-T |
Synonyms CD19-UCART - EdiGene, ET 02, ET-02 + [3] |
Target |
Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization EdiGene Inc.Startup |
Active Organization |
Inactive Organization |
Drug Highest PhaseClinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-Hodgkin Lymphoma | Preclinical | CN | - |